NHLBI Type II Coronary Intervention Study

• Status: Completed
• Trial end date: 1976-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Cholestyramine Resin

Criteria

Men and women with angiographically demonstrated coronary artery disease.